Recent updates in autonomic research: advances in the understanding of autonomic dysfunction after spinal cord injury

Lucci, Vera-Ellen M

doi:10.1007/s10286-023-00944-y

Cited by 1 publication

(1 citation statement)

References 15 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, chronic SCS may induce axon sprouting, myelin preservation, and remyelination around the lesion site to promote neuroplastic changes within the spinal autonomic circuits, which has been noted in rodent models of SCI. 1 , 26 , 27 However, concrete mechanistic evidence is still lacking to support these hypotheses.…”

Section: Introductionmentioning

confidence: 99%

Transcutaneous Spinal Cord Stimulation to Stabilize Seated Systolic Blood Pressure in Persons With Chronic Spinal Cord Injury: Protocol Development

Peters,

Harel,

Weir

et al. 2023

Neurotrauma Reports

View full text Add to dashboard Cite

Transcutaneous spinal cord stimulation (tSCS) is an emerging therapeutic strategy to target spinal autonomic circuitry to normalize and stabilize blood pressure (BP) in hypotensive persons living with chronic spinal cord injury (SCI). Our aim is to describe our current methodological approach to identify individual tSCS parameters that result in the maintenance of seated systolic blood pressure (SBP) within a pre-defined target range. The parent study is a prospective, randomized clinical trial in which eligible participants will undergo multiple mapping sessions to optimize tSCS parameter settings to promote stable SBP within a target range of 110–120 mm Hg for males and 100–120 mm Hg for females. Parameter mapping includes cathode electrode placement site (T7/8, T9/10, T11/12, and L1/2), stimulation frequency (30, 60 Hz), current amplitudes (0–120 mA), waveform (mono- and biphasic), pulse width (1000 μs), and use of carrier frequency (0, 10 kHz). Each participant will undergo up to 10 mapping sessions involving different electrode placement sites and parameter settings. BP will be continuously monitored throughout each mapping session. Stimulation amplitude (mA) will be increased at intervals of between 2 and 10 mA until one of the following occurs: 1) seated SBP reaches the target range; 2) tSCS intensity reaches 120 mA; or 3) the participant requests to stop. Secondary outcomes recorded include 1) symptoms related to autonomic dysreflexia and orthostatic hypotension, 2) Likert pain scale, and 3) skin appearance after removal of the tSCS electrode. Clinical Trials Registration: NCT05180227

show abstract

Section: Introductionmentioning

confidence: 99%